Cessation therapeutics announces oral presentation of preliminary findings from first-in-human study of anti-fentanyl monoclonal antibody, csx-1004

Chapel hill, n.c.--(business wire)--cessation therapeutics announces oral presentation of preliminary findings from first-in-human study of anti-fentanyl monoclonal antibody, csx-1004.

CSX Ratings Summary

CSX Quant Ranking